Antitumor Immunity from Abdominal Flap-Embedded Therapeutic Cancer Vaccine

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Eppenberger-Castori S, Kueng W, Benz C, et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol. 2001;19:645–656. doi:10.1200/JCO.2001.19.3.645
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377–384. doi:10.1016/S0140-6736(09)61964-4
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–734. doi:10.1056/NEJMoa1413513
   PubMed Web of Science ®Google Scholar
• Mohd Sharial MSN, Crown J, Hennessy BT. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol. 2012;23:3007–3016. doi:10.1093/annonc/mds200
   PubMed Web of Science ®Google Scholar
• Wang J, Tang Y, Jing H, et al. Risk stratification for prediction of locoregional recurrence in patients with pathologic T1-2N0 breast cancer after mastectomy. BMC Cancer. 2020;20:1132. doi:10.1186/s12885-020-07594-7
   PubMed Web of Science ®Google Scholar
• Melamed R, Rosenne E, Shakhar K, et al. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun. 2005;19:114–126. doi:10.1016/j.bbi.2004.07.004
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–2121. doi:10.1056/NEJMoa1809615
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:10.1126/science.aaa8172
   PubMed Web of Science ®Google Scholar
• Miliotou AN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018;19(1):5–18. doi:10.2174/1389201019666180418095526
   PubMed Web of Science ®Google Scholar
• Sutherland SIM, Ju X, Horvath LG, et al. Moving on from sipuleucel-T: new dendritic cell vaccine strategies for prostate cancer. Front Immunol. 2021;12:641307. doi:10.3389/fimmu.2021.641307
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi:10.1126/science.1235122
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421. doi:10.1038/nature12477
   PubMed Web of Science ®Google Scholar
• Kim A, Lee SJ, Kim YK, et al. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Sci Rep. 2017;7(1):11671. doi:10.1038/s41598-017-11905-7
   PubMed Web of Science ®Google Scholar
• Xu J, Bao H, Wu X, et al. Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer. Oncol Lett. 2019;18(1):449–455. doi:10.3892/ol.2019.10287
   PubMed Web of Science ®Google Scholar
• Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10(17):5650–5655. doi:10.1158/1078-0432.CCR-04-0225
   PubMed Web of Science ®Google Scholar
• Chamani R, Ranji P, Hadji M, et al. Application of E75 peptide vaccine in breast cancer patients: a systematic review and meta-analysis. Eur J Pharmacol. 2018;831:87–93. doi:10.1016/j.ejphar.2018.05.010
   PubMed Web of Science ®Google Scholar
• Kuan EL, Ivanov S, Bridenbaugh EA, et al. Collecting lymphatic vessel permeability facilitates adipose tissue inflammation and distribution of antigen to lymph node-homing adipose tissue dendritic cells. J Immunol. 2015;194:5200–5210. doi:10.4049/jimmunol.1500221
   PubMed Web of Science ®Google Scholar
• Xiao L, Yang X, Lin Y, et al. Large adipocytes function as antigen-presenting cells to activate CD4(+) T cells via upregulating MHCII in obesity. Int J Obes. 2016;40:112–120. doi:10.1038/ijo.2015.145
   Web of Science ®Google Scholar
• Thomalla M, Schmid A, Neumann E, et al. Evidence of an anti-inflammatory toll-like receptor 9 (TLR 9) pathway in adipocytes. J Endocrinol. 2019;240:325–343. doi:10.1530/JOE-18-0326
   PubMed Web of Science ®Google Scholar
• Karapetyan L, Luke JJ, Davar D. Toll-like receptor 9 agonists in cancer. Onco Targets Ther. 2020;13:10039–10060. doi:10.2147/OTT.S247050
   PubMed Web of Science ®Google Scholar
• Xia X, Mai J, Xu R, et al. Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. Cell Rep. 2015;11:957–966. doi:10.1016/j.celrep.2015.04.009
   PubMed Web of Science ®Google Scholar
• Mai J, Li Z, Xia X, et al. Synergistic activation of antitumor immunity by a particulate therapeutic vaccine. Adv Sci. 2021;8:2100166. doi:10.1002/advs.202100166
   Web of Science ®Google Scholar
• Womac DJ, Palanisamy AP, Eslick R, et al. Development of a mouse model of abdominal cutaneous flaps for breast reconstruction. PLoS One. 2013;8(1):e52829. doi:10.1371/journal.pone.0052829
   PubMed Web of Science ®Google Scholar
• Shen H, You J, Zhang G, et al. Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater. 2012;1:84–89. doi:10.1002/adhm.201100005
   PubMed Web of Science ®Google Scholar
• Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol. 2017;17:349–362. doi:10.1038/nri.2017.28
   PubMed Web of Science ®Google Scholar
• Santosa KB, Qi J, Kim HM, et al. Long-term patient-reported outcomes in postmastectomy breast reconstruction. JAMA Surg. 2018;153(10):891–899. doi:10.1001/jamasurg.2018.1677
   PubMed Web of Science ®Google Scholar
• Pusic AL, Matros E, Fine N, et al. Patient-Reported outcomes 1 year after immediate breast reconstruction: results of the Mastectomy Reconstruction Outcomes Consortium Study. J Clin Oncol. 2017;35(22):2499–2506. doi:10.1200/JCO.2016.69.9561
   PubMed Web of Science ®Google Scholar
• Tai LH, de Souza CT, Belanger S, et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 2013;73:97–107. doi:10.1158/0008-5472.CAN-12-1993
   PubMed Web of Science ®Google Scholar
• Ananth AA, Tai LH, Lansdell C, et al. Surgical stress abrogates pre-existing protective T cell mediated anti-tumor immunity leading to postoperative cancer recurrence. PLoS One. 2016;11:e0155947. doi:10.1371/journal.pone.0155947
   PubMed Web of Science ®Google Scholar
• Krall JA, Reinhardt F, Mercury OA, et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci Transl Med. 2018;10(436). doi:10.1126/scitranslmed.aan3464
   PubMed Web of Science ®Google Scholar
• Tanaka T, Mangala LS, Vivas-Mejia PE, et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010;70:3687–3696. doi:10.1158/0008-5472.CAN-09-3931
   PubMed Web of Science ®Google Scholar
• Ribechini E, Leenen PJ, Lutz MB. Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells. Eur J Immunol. 2009;39:3538–3551. doi:10.1002/eji.200939530
   PubMed Web of Science ®Google Scholar
• He W, Liang P, Guo G, et al. Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with cationic polymers for cancer immunotherapy. Sci Rep. 2016;6:24506. doi:10.1038/srep24506
   PubMed Web of Science ®Google Scholar
• Zoglmeier C, Bauer H, Noerenberg D, et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res. 2011;17:1765–1775. doi:10.1158/1078-0432.CCR-10-2672
   PubMed Web of Science ®Google Scholar
• Shirota H, Tross D, Klinman DM. CpG oligonucleotides as cancer vaccine adjuvants. Vaccines. 2015;3:390–407. doi:10.3390/vaccines3020390
   PubMed Web of Science ®Google Scholar
• Alicea-Torres K, Sanseviero E, Gui J, et al. Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nat Commun. 2021;12:1717. doi:10.1038/s41467-021-22033-2
   PubMed Web of Science ®Google Scholar
• Soedono S, Cho KW. Adipose tissue dendritic cells: critical regulators of obesity-induced inflammation and insulin resistance. Int J Mol Sci. 2021;22(16):8666. doi:10.3390/ijms22168666
   PubMed Web of Science ®Google Scholar
• Woodall MJ, Neumann S, Campbell K, et al. The effects of obesity on anti-cancer immunity and cancer immunotherapy. Cancers. 2020;12(5):1230. doi:10.3390/cancers12051230
   PubMed Web of Science ®Google Scholar
• Deng T, Lyon CJ, Minze LJ, et al. Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab. 2013;17(3):411–422. doi:10.1016/j.cmet.2013.02.009
   PubMed Web of Science ®Google Scholar